A Bayesian Re-analysis of the GALFLU Trial of High-Dose vs Standard-Dose Influenza Vaccine Against Hospitalization Outcomes
Year: 2026
Type: article
Abstract: The GALFLU trial showed a lower incidence of hospitalization among adults aged 65-79 years randomized to high-dose inactivated influenza vaccine (HD-IIV) vs standard-dose inactivated influenza vaccine (SD-IIV). This Bayesian re-analysis estimated >80% probability of benefit (relative vaccine effectiveness >10%) against influenza- or pneumonia-related hospitalization, supporting the benefit of HD-IIV over SD-IIV. Clinical Trials Registration. GALFLU ClinicalTrials.gov (NCT06141655); EudraCT (2023-506977-36-00).
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/ciag466
Authors: Jacobo Pardo-Seco, Carmen Rodriguez-Tenreiro-Sánchez, Iago Giné-Vázquez, Narmeen Mallah, Susana Mirás-Carballal, Marta Piñeiro-Sotelo, Martín Cribeiro González, Mónica Conde Pájaro, Juan-Manuel González-Pérez, Irene Rivero-Calle, Xabier Bello, Josefina L Razzini, Antonio Salas, Rebecca C Harris, Matthew M Loiacono, Robertus van Aalst, Manel Farre, Marine Dufournet, Niklas Dyrby Johansen, Daniel Modin, Tor Biering-Sørensen, Carmen Duran-Parrondo, Federico Martinón-Torres
Institutions: Universidade de Santiago de Compostela, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, Instituto de Investigación Sanitaria de Santiago, Servicio Gallego de Salud, Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública, Xunta de Galicia, Sanofi (United States), University of Delaware, Sanofi (Spain), Sanofi (France), University of Copenhagen, Copenhagen University Hospital, Gentofte Hospital, Rigshospitalet, Steno Diabetes Center Copenhagen
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,763
Awards: G3597462280, G5726186210
OpenAlex ID: W7172326579